Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.
Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.
Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.
An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.
Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.
Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.
Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.
Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.
Enzalutamide plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared with ADT alone.
Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.